A Evaluation of SGOT and SGPT Parameters as Indicators of Liver Function in Tuberculosis Patients During OAT Therapy: Literature Review
Evaluasi Parameter SGOT dan SGPT sebagai Indikator Fungsi Hati pada Pasien Tuberkulosis Selama Terapi OAT: Literature Review
DOI:
https://doi.org/10.21070/pels.v10i1.2982Keywords:
Tuberculosis, Anti-Tuberculosis Therapy, Transaminase Enzymes, Hepatic Function, HepatotoxicityAbstract
General Background Tuberculosis remains a major global infectious disease requiring prolonged anti-tuberculosis drug therapy. Specific Background First-line therapeutic regimens containing isoniazid, rifampicin, and pyrazinamide commonly induce drug-induced liver injury, which requires clinical monitoring through serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase levels. Knowledge Gap Although transaminase elevations are frequently observed during treatment, variations in the onset, severity, and predisposing risk factors across diverse clinical populations require systematic synthesis. Aims This literature review evaluates alterations in transaminase enzyme levels as indicators of hepatic function in tuberculosis patients undergoing drug therapy. Results Synthesis of twenty empirical studies published between 2020 and 2025 demonstrates that transaminase elevations occur predominantly during the intensive treatment phase, with significant risk exacerbation observed in elderly patients, prolonged therapy durations, specific drug regimens, and underlying hepatic comorbidities. Novelty Systematic mapping of multi-study evidence clarifies the transition dynamics between transient adaptive enzyme elevations and severe drug-induced hepatotoxicity across different treatment phases. Implications Routine monitoring of liver transaminase parameters is essential for early detection of drug-induced liver injury and ensuring therapeutic safety in tuberculosis management.
Key Findings Highlights
Transaminase Elevation Occurs Predominantly During Intensive Therapy Phase
Advanced Age And Hepatic Comorbidities Exacerbate Hepatotoxicity Risk
Periodic Enzyme Monitoring Ensures Patient Safety During Tuberculosis Treatment
Keywords Tuberculosis, Anti-Tuberculosis Therapy, Transaminase Enzymes, Hepatic Function, Hepatotoxicity
Downloads
References
S. A. Rasyid, T. Mayang, and P. Lio, "Analysis of serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase levels in tuberculosis patients who are undergoing OAT treatment in Kendari City General Hospital, Kota Kendari, Indonesia," Infectious Disease Reports, vol. 12, pp. 75–77, 2020, doi: 10.4081/idr.2020.8732.
World Health Organization, Global Tuberculosis Report 2023. Geneva, Switzerland: World Health Organization, 2023.
T. P. Syalia, D. Indarsita, and H. F. Pane, "Examination of SGOT-SGPT levels in the elderly tuberculosis patients," Journal of Medical Laboratory Technology, vol. 4, no. 1, pp. 9–13, 2022.
N. A. Yudhaswara, N. M. Susilawati, and S. D. Udju, "Hubungan lama pengobatan dengan kadar SGOT dan SGPT pada pasien tuberkulosis," Jurnal Kesehatan Terpadu, vol. 7, no. 2, pp. 299–306, 2023.
D. P. Sari and E. Sitompul, "Pengaruh terapi OAT (Obat Anti Tuberkulosis) dan faktor risiko terhadap kejadian hepatotoksisitas pada pasien TB paru di RSUD Pasar Rebo," Jurnal Farmasi Klinik Indonesia, vol. 14, no. 1, pp. 45–53, 2025.
Warsyidah and A. A. S. Y. P. S. Sari, "Gambaran SGOT dan SGPT pada penderita penyakit tuberculosis paru (TB) dalam masa pengobatan 6 bulan di Rumah Sakit Umum Wisata Universitas Indonesia Timur," Jurnal Media Laboratorium Kesehatan, vol. 10, no. 2, pp. 6–10, 2020.
N. P. A. D. U. R. Sari, S. Hayati, and N. Foekh, "Perbandingan kadar SGOT dan SGPT sebelum dan sesudah pengobatan pada pasien tuberkulosis resisten obat," Jurnal Biomedis dan Kesehatan, vol. 3, no. 2, pp. 112–119, 2025.
M. A. Makaminan, M. Vallery, L. Tumbol, and J. E. Sumampouw, "Description of liver function on the effect of treatment on pulmonary tuberculosis patients at the Manado City Health Center," Journal of Health Sciences, vol. 5, no. 1, pp. 1–11, 2022.
F. B. Sabiti and N. A. C. Sa'dyah, "The relationship between side effects of tuberculosis drug use and SGOT/SGPT value of pulmonary TB patients," Indonesian Journal of Tropical and Infectious Disease, vol. 8, no. 3, pp. 281–285, 2022.
W. A. Putra, I. G. A. A. Kusumadjaja, and I. M. D. Sukrama, "Characteristic of SGOT and SGPT elevation in patient with lung tuberculosis within OAT therapy," Bali Medical Journal, vol. 37, pp. 92–98, 2021.
M. D. Sekarwati, "Perbedaan kadar enzim SGOT dan SGPT pada pasien tuberkulosis paru yang sedang mengonsumsi Obat Anti Tuberkulosis (OAT) dalam fase intensif dan fase lanjutan," Jurnal Analis Kesehatan, vol. 2, no. 4, pp. 338–349, 2025.
S. Wabula, H. Hidayat, and N. A. R. Ahmad, "Analisis kadar SGOT dan SGPT pada pasien tuberkulosis dalam pengobatan OAT di RSU PKU Muhammadiyah Yogyakarta," Jurnal Sains dan Kesehatan, vol. 5, no. 5, pp. 9152–9158, 2024.
D. Salbiah, D. Indarsita, H. F. Pane, and Y. A. Fadila, "Analisis kadar serum glutamic pyruvic transaminase dan serum glutamic oxaloacetic transaminase pada pasien tuberkulosis yang menjalani pengobatan obat anti tuberkulosis," Jurnal Riset Kimia dan Laboratorium, vol. 4, no. 2, pp. 147–152, 2023.
N. Hasanah, T. O. Ratnaningtyas, and A. Razana, "Pengaruh obat anti tuberkulosis terhadap nilai SGPT dan SGOT berdasarkan usia dan jenis kelamin pasien tuberkulosis paru di RS Sari Asih Ciputat," Pharma Journal of Indonesia, vol. 9, no. 2, pp. 10–16, 2020, doi: 10.30591/pjif.v9i2.1842.
E. S. Wahyuni and B. Sudrajat, "Gambaran nilai SGPT pasien tuberkulosis dengan penggunaan OAT di Rumah Sakit DKH Kedungwaringin," Jurnal Farmasi Medika, vol. 3, no. 1, pp. 7–11, 2024.
G. Stephanie, M. R. T. A. Pratama, and S. M. L. Tobing, "Gambaran kadar SGOT dan SGPT pada pasien tuberkulosis paru aktif," Jurnal Kedokteran Indonesia, vol. 9, no. 3, pp. 509–514, 2021.
Ahmed, M. K. Khan, and R. A. Memon, "To observe the hepatotoxicity with anti-tuberculosis drugs and its frequency and severity," Journal of Ayub Medical College, vol. 11, no. 2, pp. 57–60, 2021.
R. Kumar, S. P. Rai, and A. K. Sharma, "A study to detect liver enzyme dysfunction among patients on first line anti-tubercular drugs from RNTCP during the course of anti-TB treatment," Journal of Evolution of Medical and Dental Sciences, vol. 9, no. 9, pp. 645–650, 2020, doi: 10.14260/jemds/2020/141.
S. W. Chairini and A. Widodo, "Gambaran pemeriksaan kadar SGOT dan SGPT pada penderita tuberculosis paru," Jurnal Laboratorium Medis, vol. 2, no. 1, pp. 34–37, 2020.
W. Rustiah, N. Rahman, and T. L. Medis, "Gambaran kadar Serum Glutamic Pyruvic Transaminase (SGPT) pada penderita tuberkulosis pengobatan 6 bulan – 1 tahun," Jurnal Media Kesehatan, vol. 3, no. 2, pp. 96–103, 2022.
S. Siregar, M. H. Nasution, and A. R. Lubis, "Analysis of liver function and haemoglobin levels in pulmonary tuberculosis patients with anti-tuberculosis drug," Journal of Clinical Pathology and Laboratory Medicine, vol. 10, no. 12, pp. 336–341, 2024.
R. S. Patil, S. B. Kulkarni, and V. M. Joshi, "Assessment of drug-induced liver injury secondary to first-line anti-tuberculosis therapy: A prospective observational study," Indian Journal of Tuberculosis, vol. 72, no. 2, pp. 185–192, 2025, doi: 10.1016/j.ijtb.2024.08.004.
M. T. H. Minh, L. T. N. Anh, and N. V. Bang, "Patterns of transaminase elevation and clinical outcomes in patients receiving anti-tuberculosis treatment," Tropical Medicine and Infectious Disease, vol. 10, no. 3, art. no. 88, 2025, doi: 10.3390/tropicalmed10030088.
J. H. Kim, Y. S. Lee, and S. M. Park, "Early predictor markers for anti-tuberculosis drug-induced hepatotoxicity during the intensive treatment phase," BMC Infectious Diseases, vol. 24, art. no. 1012, 2024, doi: 10.1186/s12879-024-09852-1.
E. A. Fernandez, C. M. Santos, and R. L. Gomez, "Age and comorbid liver disease as key risk factors for severe transaminase elevation in tuberculosis treatment," International Journal of Infectious Diseases, vol. 142, art. no. 106981, 2024, doi: 10.1016/j.ijid.2024.106981.
S. K. Sharma and P. K. Singla, "Monitoring strategies for anti-tuberculosis drug-induced liver injury: A systematic review and meta-analysis," The Lancet Infectious Diseases, vol. 26, no. 4, pp. 450–462, 2026, doi: 10.1016/S1473-3099(25)00312-8.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Lili Furqonati, Maya, Eri Irsyadiyah Elvaretta, Aulia Azzahra, Muhammad Guntur Dwi Firmansyah, Kinanti Defin Nurani, Puspitasari
This work is licensed under a Creative Commons Attribution 4.0 International License.
